

Additional file 1. Definition of subsequent (second-line) treatments

Molecular diagnosis		First-line treatment	Second-line treatment			
			Active treatment		Non-treatment	
			%	Treatment	%	Treatment
ALK+		Alectinib	80,00%	<i>Cisp + pmtrx</i>	20,00%	<i>BSC</i>
		Crizotinib	80,00%	<i>alectinib</i>	20,00%	<i>BSC</i>
EGFR+		Erlotinib	70,00%	<i>osimertinib</i>	30,00%	<i>BSC</i>
		Gefitinib	70,00%	<i>osimertinib</i>	30,00%	<i>BSC</i>
		Afatinib	70,00%	<i>osimertinib</i>	30,00%	<i>BSC</i>
		Osimertinib	70,00%	<i>Cisp + pmtrx</i>	30,00%	<i>BSC</i>
ROS1+		Crizotinib	80,00%	<i>Cisp + pmtrx</i>	20,00%	<i>BSC</i>
WT	TPS≥50%	Pembrolizumab	60,80%	<i>Cisp + pmtrx</i>	39,20%	<i>BSC</i>
	TPS<50%	<i>Cisp + pmtrx</i>	46,60%	<i>Inmunotherapies^a (75%); docetaxel + nintedanib (25%)</i>	53,40%	<i>BSC</i>
		<i>Carb+ paclitx + bev</i>	46,60%		53,40%	<i>BSC</i>
		<i>Cisp + pmtrx + pembro</i>	30,50%		69,50%	<i>BSC</i>

ALK: anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; WT: wild-type; TPS: tumor proportion score; Cisp: cisplatin; Carb: carboplatin; pmtrx: pemetrexed; paclitx: paclitaxel; bev: bevacizumab; BSC: best supportive care.

^a Atezolizumab, pembrolizumab and nivolumab